Search

Xenon Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

41.62 2.16

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

40.54

Max

41.77

Galvenie mērījumi

By Trading Economics

Ienākumi

301K

-110M

EPS

-1.11

Darbinieki

358

EBITDA

-9.3M

-120M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+77.64% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

274M

3.9B

Iepriekšējā atvēršanas cena

39.46

Iepriekšējā slēgšanas cena

41.62

Xenon Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. nov. 20:51 UTC

Social Media
News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million, and advances its drug pipeline.

2026. g. 9. nov. 23:02 UTC

News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million loss, with operating expenses rising to $120.1 million.

2026. g. 6. nov. 21:03 UTC

Xenon Pharmaceuticals Inc. is trading higher, diverging from a downward shift in the broader market despite recent upward momentum in prior sessions.

2026. g. 5. nov. 22:11 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-market hours amid a broader market decline.

2026. g. 4. nov. 21:07 UTC

Xenon Pharmaceuticals Inc. gained significantly during Wednesday's trading, maintaining strong upward momentum and finishing above its 20-day moving average since Tuesday's close.

2026. g. 3. nov. 21:07 UTC

Xenon Pharmaceuticals Inc. is trading higher, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

2026. g. 2. nov. 20:52 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, positioned above its 20-day moving average and near the upper end of its one-month range.

2026. g. 30. okt. 20:08 UTC

Social Media
News

Stifel sets a price target of $86 for Xenon Pharmaceuticals and maintains a "Buy" rating, citing the company's developing pipeline for epilepsy treatments.

2026. g. 29. okt. 20:04 UTC

News
Social Media

Xenon Pharmaceuticals reports positive Phase 1 results for XEN1701 and XEN1120, supporting progression to Phase 2 studies in acute pain, presented at IASP 2026.

2026. g. 28. okt. 19:36 UTC

Xenon Pharmaceuticals Inc. is seeing a modest advance on Wednesday, marking three consecutive sessions of gains despite a slight pullback from its mid-morning peak.

2026. g. 27. okt. 20:07 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, settling in the middle of its one-month trading range after a brief dip earlier in the day.

2026. g. 23. okt. 20:01 UTC

Xenon Pharmaceuticals Inc shares are declining, reversing recent gains and reflecting a downward shift since Thursday's close.

2026. g. 22. okt. 19:41 UTC

Xenon Pharmaceuticals Inc is experiencing higher price movement, supported by significant gains in the Biotechnology sub-sector, trading within the middle of its one-month range.

2026. g. 21. okt. 23:46 UTC

Xenon Pharmaceuticals Inc shares are trading lower in after-market hours, following a notable drop from an earlier high amid broader market weakness.

2026. g. 20. okt. 20:02 UTC

Xenon Pharmaceuticals Inc shares are advancing, having reached a peak earlier in the session, marking a significant increase within its one-month trading range.

2026. g. 19. okt. 20:02 UTC

Xenon Pharmaceuticals Inc shares are gaining amid a broader market trend of higher daily closes since Friday's close.

2026. g. 16. okt. 20:02 UTC

Xenon Pharmaceuticals Inc shares are declining sharply, continuing a downward trend since Thursday and remaining significantly below their 20-day moving average.

2026. g. 15. okt. 20:03 UTC

Xenon Pharmaceuticals Inc shares are advancing, influenced by a significant upward movement in the Biotechnology sub-sector, despite earlier pulling back from a session high.

2026. g. 14. okt. 19:21 UTC

Xenon Pharmaceuticals Inc shares fell significantly, continuing a downward trend with three consecutive sessions of losses and remaining below its 20-day moving average.

2026. g. 13. okt. 20:01 UTC

Xenon Pharmaceuticals Inc shares fell, breaking a trend of higher daily closes, contrasting with recent upward momentum since Monday's close.

2026. g. 9. okt. 20:06 UTC

Xenon Pharmaceuticals Inc shares are modestly higher, peaking in early afternoon trading.

2026. g. 8. okt. 19:15 UTC

Xenon Pharmaceuticals Inc shares are declining, marking five consecutive sessions lower, and remain significantly below their 20-day moving average amid ongoing market weakness.

2026. g. 6. okt. 20:02 UTC

Xenon Pharmaceuticals Inc shares fell sharply, continuing a downward trend with unusually high volume and remaining below the 20-day moving average.

2026. g. 5. okt. 20:06 UTC

News

Xenon Pharmaceuticals Inc shares are declining, continuing a trend from Friday's close, despite an earlier rebound from a session low.

2026. g. 2. okt. 21:01 UTC

News

Xenon Pharmaceuticals Inc announced equity inducement grants to new employees, with after-market trading showing a slight gain since Friday's close.

2026. g. 1. okt. 23:55 UTC

Xenon Pharmaceuticals Inc declined in after-market trading, moving lower since Thursday's close and remaining significantly below its 20-day moving average.

2026. g. 30. sept. 20:07 UTC

Xenon Pharmaceuticals Inc. shares fell, closing lower than Tuesday's close after an early drop, remaining below its 20-day moving average.

2026. g. 29. sept. 20:01 UTC

Xenon Pharmaceuticals Inc is advancing today with increased trading volume, recovering from earlier losses to reach a peak in late morning.

2026. g. 28. sept. 23:55 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-hours, shifting from a slight gain to a more substantial loss since Monday's close, remaining below its 20-day moving average.

2026. g. 25. sept. 20:01 UTC

Xenon Pharmaceuticals Inc shares fell sharply, pressured by broader biotechnology sector weakness, and are nearly 3% below Thursday's close.

Salīdzinājums

Cenas izmaiņa

Xenon Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

77.64% augšup

Prognoze 12 mēnešiem

Vidējais 69.583 USD  77.64%

Augstākais 90 USD

Zemākais 46 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Xenon Pharmaceuticals Inc  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

15

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat